Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells
Yıl: 2021 Cilt: 18 Sayı: 1 Sayfa Aralığı: 75 - 79 Metin Dili: İngilizce DOI: 10.4274/tjps.galenos.2019.04657 İndeks Tarihi: 20-05-2022
Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells
Öz: Objectives: Probucol is a bisphenol antioxidant with antiinflammatory, antilipidemic and antidiabetic effect. Development and progression of cancer is closely related to chronic inflammation and oxidative stress. Agents that target these processes have been shown to modulate cancer cell proliferation. In this regard, the effect of probucol on proliferation of different cancer cell lines was investigated. Materials and Methods: Different concentrations of probucol solutions were prepared and applied to the following cancer cell lines: K562S (imatinib sensitive) and K562R (imatinib resistant) chronic myeloid leukemia (CML) cells; U937 histiocytic lymphoma cells; HL60 acute myeloid leukemia cells; U266, H929, and RPMI8226 multiple myeloma cells; and L929 fibroblast cells. Cell viability was conducted by 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide assay. Results: Significant toxicity was not exhibited due to probucol treatment (0.1-10 µM) in K562S and K562R CML cells, U937 histiocytic lymphoma cells, HL60 acute myeloid leukemia cells, U266 multiple myeloma cells, and L929 fibroblast cells. However, probucol treatment significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells at the concentration of 0.5-10 µM and 5-10 µM, respectively. Conclusion: Probucol treatment slightly inhibited the viability of other cancer cell lines, but significantly inhibited the viability of H929 and RPMI8226 multiple myeloma cells. However, its effect was not potent, since a 50% reduction in cell viability could not be achieved at the concentrations of probucol treatment administered. Key words: Probucol, chronic myeloid leukemia, multiple myeloma, histiocytic lymphoma, acute myeloid leukemia
Anahtar Kelime: Probukolün Lösemi, Multipl Miyeloma, Lenfoma ve Fibroblast Hücre Hatlarının Proliferasyonu Üzerindeki Etkileri
Öz: Amaç: Probukol, antiinflamatuvar, antilipidemik ve antidiyabetik aktivitelere sahip bisfenol bir antioksidandır. Kanser gelişimi ve ilerlemesi kronik inflamasyon ve oksidatif stres ile yakından ilişkilidir ve bu süreçleri hedefleyen ajanların kanser hücre proliferasyonunu modüle ettikleri gösterilmiştir. Bu bağlamda, bu çalışmada, probukolün farklı kanser hücre hatlarının proliferasyonu üzerindeki etkileri araştırılmıştır. Gereç ve Yöntemler: Probukolün farklı konsantrasyonlarda hazırlanan çözeltileri kullanılarak K562S (imatinib duyarılı), K562R (imatinib dirençli) kronik miyeloid lösemi (KML), U937 histiositik lenfoma, HL60 akut miyeloid lösemi, U266 multipl miyeloma ve L929 fibroblast hücre hatlarında hücre canlılığı 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium testi ile belirlenmiştir. Bulgular: Probukol uygulaması (0,1 µM-10 µM), K562S, K562R KML, U937 histositik lenfoma, HL60 akut miyeloid lösemi, U266, H929, RPMI8226 multipl miyelom ve L929 fibroblast hücre hatlarında anlamlı bir etki göstermemiştir. Diğer taraftan, probukol uygulaması, H929 ve RPMI8226 hücre serilerinin canlılığını sırasıyla 0,5-10 µM and 5-10 µM konsantrasyon aralığında anlamlı olarak azaltmıştır (p<0,05). Sonuç: Probukol uygulaması H929 ve RPMI8226 multipl miyelom hücre hatlarının canlılığını anlamlı olarak inhibe etmiştir. Fakat, probukolün bu etkisi potent bulunmamıştır ve uygulanan konsantrasyon aralığında, hücre canlılığında %50 ve üzerinde azalma sergilemediği belirlenmiştir. Anahtar kelimeler: Probukol, kronik miyeloid lösemi, multipl miyelom, histositik lenfoma, akut miyeloid lösemi
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Heel RC, RN Brogden, TM Speight, GS Avery. Probucol: A review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs. 1978;15:409-428.
- 2. Buckley MM, KL Goa, AH Price, RN Brogden. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989;37:761-800.
- 3. Parthasarathy S, SG Young, JL Witztum, RC Pittman, D Steinberg. Probucol inhibits oxidative modification of low density lipoprotein. The Journal of clinical investigation. 1986;77:641-644.
- 4. Yamashita S, D Masuda, Y Matsuzawa. Did we abandon probucol too soon? Current opinion in lipidology.2015;26:304-316.
- 5. Takechi R, MM Pallebage-Gamarallage, V Lam, C Giles, JC Mamo. Longterm probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. Lipids in health and disease. 2014;13:91.
- 6. Keyamura Y, C Nagano, M Kohashi, M Niimi, M Nozako, T Koyama, R Yasufuku, A Imaizumi, H Itabe, T Yoshikawa. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin. PloS one. 2014;9:e96929.
- 7. Mamo JC, V Lam, E Brook, A Mooranian, H Al-Salami, N Fimognari, M Nesbit, R Takechi. Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes & vascular disease research. 2019;16:87-97.
- 8. Ribeiro RP, EL Moreira, DB Santos, D Colle, AA Dos Santos, KC Peres, CP Figueiredo, M Farina. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson’s disease. Neurochemical Research. 2013;38:660-668.
- 9. Colle D, Santos DB, Moreira EL, Hartwig JM, dos Santos AA, Zimmermann LT, Hort MA, Farina M. Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. PLoS One. 2013;14;8:e67658.
- 10. Mooranian A, Zamani N, Luna G, Al-Sallami H, Mikov M, Goločorbin-Kon S, Stojanovic G, Arfuso F, Kovacevic B, Al-Salami H. Bile acid-polymerprobucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model. Pharm Dev Technol. 2019;24:1272-1277.
- 11. Zucoloto AZ, Manchope MF, Borghi SM, Dos Santos TS, Fattori V, Badaro-Garcia S, Camilios-Neto D, Casagrande R, Verri WA Jr. Probucol Ameliorates Complete Freund’s Adjuvant-Induced Hyperalgesia by Targeting Peripheral and Spinal Cord Inflammation. Inflammation. 2019;42:1474-1490.
- 12. Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV, Krasnov GS, Dmitriev AA. ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells. Oxid Med Cell Longev. 2019;2019:6175804.
- 13. Hanikoglu A, Ozben H, Hanikoglu F, Ozben T. Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy. Curr Med Chem. 2020;27:2118-2132.
- 14. Udensi UK, Tchounwou PB. Dual effect of oxidative stress on leukemia cancer induction and treatment. J Exp Clin Cancer Res. 2014;33:106.
- 15. Agarwal A, Muñoz-Nájar U, Klueh U, Shih SC, Claffey KP. N-acetylcysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol. 2004;164:1683-1696.
- 16. Fontana F, Moretti RM, Raimondi M, Marzagalli M, Beretta G, Procacci P, Sartori P, Montagnani Marelli M, Limonta P. δ-Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells. Cell Prolif. 2019;52:e12576.
- 17. Zan L, Chen Q, Zhang L, Li X. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25. Bioengineered. 2019;10:374-382.
- 18. Zeng LH, Wang QM, Feng LY, Ke YD, Xu QZ, Wei AY, Zhang C, Ying RB. High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. Onco Targets Ther. 2019;12:7405-7413.
- 19. Sun C, Zhang S, Liu C, Liu X. Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells. Cancer Biother Radiopharm. 2019;34:634-641.
- 20. Sarkar R, Mukherjee A, Mukherjee S, Biswas R, Biswas J, Roy M. Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6. J Environ Pathol Toxicol Oncol. 2014;33:247-263.
- 21. Mastrangelo D, Massai L, Lo Coco F, Noguera NI, Borgia L, Fioritoni G, Berardi A, Iacone A, Muscettola M, Pelosi E, Castelli G, Testa U, Di Pisa F, Grasso G. Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines. Ann Hematol. 2015;9:1807-1816.
- 22. Li RF, Feng YQ, Chen JH, Ge LT, Xiao SY, Zuo XL. Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycininduced oxidative damage in polymorphonuclear leukocytes. Exp Ther Med. 2015;9:697-706.
- 23. Geng W, Guo X, Zhang L, Ma Y, Wang L, Liu Z, Ji H, Xiong Y. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/beta-catenin signaling pathway. Biomed Pharmacother. 2018;107:484-494.
- 24. Najibi A, Heidari R, Zarifi J, Jamshidzadeh A, Firoozabadi N, Niknahad H. Evaluating the Role of Drug Metabolism and Reactive Intermediates in Trazodone-Induced Cytotoxicity toward Freshly-Isolated Rat Hepatocytes. Drug Res (Stuttg). 2016;66:592-596.
- 25. Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms. Cell Mol Biol (Noisy-le-Grand). 2018;64:23-30.
- 26. Zhang Z, H Cao, S Jiang, Z Liu, X He, H Yu, Y Li. Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer. Small (Weinheim an der Bergstrasse, Germany). 2014;10:4735-4745.
- 27. Zarkovic M, Qin X, Nakatsuru Y, Zhang S, Yamazaki Y, Oda H, Ishikawa T, Ishikawa T. Inhibitory effect of probucol on benzo[a]pyrene induced lung tumorigenesis. Carcinogenesis. 1995;16:2599-2601.
- 28. Chuang LY, Guh JY, Ye YL, Lee YH, Huang JS. Effects of probucol on cell proliferation in human ovarian cancer cells. Toxicol Res (Camb). 2016;5:331-339.
- 29. Iqbal M, Okazaki Y, Okada S. Probucol modulates iron nitrilotriacetate (Fe-NTA)-dependent renal carcinogenesis and hyperproliferative response: diminution of oxidative stress. Mol Cell Biochem. 2007;304:61- 69.
- 30. Nishimura G, Yanoma Y, Mizuno H, Kawakami, Tsukuda M. An antioxidant, probucol, induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells. Jpn J Cancer Res. 1999;90:1224-1230.
- 31. Kaneko M, Hayashi J, Saito I, Miyasaka N. Probucol downregulates E-selectin expression on cultured human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1996;16:1047-1051.
- 32. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ. Ginkgo biloba extract inhibits tumor necrosis factor-α–induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:1559-1566.
| APA | KOÇ A, Karabay A, Yaprak A, Buyukbingol Z, Aktan F (2021). Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. , 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| Chicago | KOÇ Asli,Karabay Arzu Zeynep,Yaprak Ali,Buyukbingol Zeliha,Aktan Fugen Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. (2021): 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| MLA | KOÇ Asli,Karabay Arzu Zeynep,Yaprak Ali,Buyukbingol Zeliha,Aktan Fugen Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. , 2021, ss.75 - 79. 10.4274/tjps.galenos.2019.04657 |
| AMA | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. . 2021; 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| Vancouver | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. . 2021; 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| IEEE | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F "Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells." , ss.75 - 79, 2021. 10.4274/tjps.galenos.2019.04657 |
| ISNAD | KOÇ, Asli vd. "Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells". (2021), 75-79. https://doi.org/10.4274/tjps.galenos.2019.04657 |
| APA | KOÇ A, Karabay A, Yaprak A, Buyukbingol Z, Aktan F (2021). Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences, 18(1), 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| Chicago | KOÇ Asli,Karabay Arzu Zeynep,Yaprak Ali,Buyukbingol Zeliha,Aktan Fugen Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences 18, no.1 (2021): 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| MLA | KOÇ Asli,Karabay Arzu Zeynep,Yaprak Ali,Buyukbingol Zeliha,Aktan Fugen Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences, vol.18, no.1, 2021, ss.75 - 79. 10.4274/tjps.galenos.2019.04657 |
| AMA | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences. 2021; 18(1): 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| Vancouver | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells. Turkish Journal of Pharmaceutical Sciences. 2021; 18(1): 75 - 79. 10.4274/tjps.galenos.2019.04657 |
| IEEE | KOÇ A,Karabay A,Yaprak A,Buyukbingol Z,Aktan F "Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells." Turkish Journal of Pharmaceutical Sciences, 18, ss.75 - 79, 2021. 10.4274/tjps.galenos.2019.04657 |
| ISNAD | KOÇ, Asli vd. "Effect of Probucol on Proliferation of Leukemia, Multiple Myeloma, Lymphoma, and Fibroblast Cells". Turkish Journal of Pharmaceutical Sciences 18/1 (2021), 75-79. https://doi.org/10.4274/tjps.galenos.2019.04657 |
